BACKGROUND: A unique genomic difference between human and civet severe acute respiratory syndrome coronaviruses (SARS-CoVs) is that the former has a deletion of 29 nucleotides from open reading frame (orf) 8a' that results in the generation of orf8a and orf8b. The objectives of the present study were to analyze antibody reactivity to ORF8a in patients with SARS and to elucidate the function of ORF8a. METHODS: Western-blot and immunofluorescent antibody assays were used to detect anti-ORF8a antibody. SARS-CoV HKU39849 was used to infect stable clones expressing ORF8a and cells transfected with small interfering RNA (siRNA). The virus loads (VLs) and cytopathic effects (CPEs) were recorded. Confocal microscopy and several mitochondria-related tests were used to study the function of ORF8a. RESULTS: Two (5.4%) of 37 patients with SARS had anti-ORF8a antibodies. The VLs in the stable clones expressing ORF8a were significantly higher than those in control subjects 5 days after infection. siRNA against orf8a significantly reduced VLs and interrupted the CPE. ORF8a was found to be localized in mitochondria, and overexpression resulted in increases in mitochondrial transmembrane potential, reactive oxygen species production, caspase 3 activity, and cellular apoptosis. CONCLUSIONS: ORF8a not only enhances viral replication but also induces apoptosis through a mitochondria-dependent pathway.
BACKGROUND: A unique genomic difference between human and civet severe acute respiratory syndrome coronaviruses (SARS-CoVs) is that the former has a deletion of 29 nucleotides from open reading frame (orf) 8a' that results in the generation of orf8a and orf8b. The objectives of the present study were to analyze antibody reactivity to ORF8a in patients with SARS and to elucidate the function of ORF8a. METHODS: Western-blot and immunofluorescent antibody assays were used to detect anti-ORF8a antibody. SARS-CoV HKU39849 was used to infect stable clones expressing ORF8a and cells transfected with small interfering RNA (siRNA). The virus loads (VLs) and cytopathic effects (CPEs) were recorded. Confocal microscopy and several mitochondria-related tests were used to study the function of ORF8a. RESULTS: Two (5.4%) of 37 patients with SARS had anti-ORF8a antibodies. The VLs in the stable clones expressing ORF8a were significantly higher than those in control subjects 5 days after infection. siRNA against orf8a significantly reduced VLs and interrupted the CPE. ORF8a was found to be localized in mitochondria, and overexpression resulted in increases in mitochondrial transmembrane potential, reactive oxygen species production, caspase 3 activity, and cellular apoptosis. CONCLUSIONS:ORF8a not only enhances viral replication but also induces apoptosis through a mitochondria-dependent pathway.
Authors: Qing-ling Zhang; Yan-qing Ding; Li He; Wei Wang; Jin-hua Zhang; Hui-jun Wang; Jun-jie Cai; Jian Geng; Yao-dan Lu; Yuan-long Luo Journal: Di Yi Jun Yi Da Xue Xue Bao Date: 2003-08
Authors: Patrick T W Law; Chi-Hang Wong; Thomas C C Au; Chi-Pang Chuck; Siu-Kai Kong; Paul K S Chan; Ka-Fai To; Anthony W I Lo; Judy Y W Chan; Yick-Keung Suen; H Y Edwin Chan; Kwok-Pui Fung; Mary M Y Waye; Joseph J Y Sung; Y M Dennis Lo; Stephen K W Tsui Journal: J Gen Virol Date: 2005-07 Impact factor: 3.891
Authors: Z Matsuda; M J Chou; M Matsuda; J H Huang; Y M Chen; R Redfield; K Mayer; M Essex; T H Lee Journal: Proc Natl Acad Sci U S A Date: 1988-09 Impact factor: 11.205
Authors: Volker Thiel; Konstantin A Ivanov; Ákos Putics; Tobias Hertzig; Barbara Schelle; Sonja Bayer; Benedikt Weißbrich; Eric J Snijder; Holger Rabenau; Hans Wilhelm Doerr; Alexander E Gorbalenya; John Ziebuhr Journal: J Gen Virol Date: 2003-09 Impact factor: 3.891
Authors: Indrapal N Singh; Robin J Goody; Celeste Dean; Nael M Ahmad; Sarah E Lutz; Pamela E Knapp; Avindra Nath; Kurt F Hauser Journal: J Neurovirol Date: 2004-06 Impact factor: 2.643
Authors: Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson Journal: N Engl J Med Date: 2003-04-10 Impact factor: 91.245
Authors: Jason Netland; Marta L DeDiego; Jincun Zhao; Craig Fett; Enrique Álvarez; José L Nieto-Torres; Luis Enjuanes; Stanley Perlman Journal: Virology Date: 2010-01-27 Impact factor: 3.616
Authors: Susanna K P Lau; Kenneth S M Li; Yi Huang; Chung-Tong Shek; Herman Tse; Ming Wang; Garnet K Y Choi; Huifang Xu; Carol S F Lam; Rongtong Guo; Kwok-Hung Chan; Bo-Jian Zheng; Patrick C Y Woo; Kwok-Yung Yuen Journal: J Virol Date: 2010-01-13 Impact factor: 5.103
Authors: Susanna K P Lau; Yun Feng; Honglin Chen; Hayes K H Luk; Wei-Hong Yang; Kenneth S M Li; Yu-Zhen Zhang; Yi Huang; Zhi-Zhong Song; Wang-Ngai Chow; Rachel Y Y Fan; Syed Shakeel Ahmed; Hazel C Yeung; Carol S F Lam; Jian-Piao Cai; Samson S Y Wong; Jasper F W Chan; Kwok-Yung Yuen; Hai-Lin Zhang; Patrick C Y Woo Journal: J Virol Date: 2015-08-12 Impact factor: 5.103
Authors: Marta L Dediego; Lecia Pewe; Enrique Alvarez; Maria Teresa Rejas; Stanley Perlman; Luis Enjuanes Journal: Virology Date: 2008-05-02 Impact factor: 3.616
Authors: Liliana Echavarría-Consuegra; Georgia M Cook; Idoia Busnadiego; Charlotte Lefèvre; Sarah Keep; Katherine Brown; Nicole Doyle; Giulia Dowgier; Krzysztof Franaszek; Nathan A Moore; Stuart G Siddell; Erica Bickerton; Benjamin G Hale; Andrew E Firth; Ian Brierley; Nerea Irigoyen Journal: PLoS Pathog Date: 2021-06-17 Impact factor: 6.823